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AbsTrACT
Objective a hallmark of amyotrophic lateral sclerosis 
(aLs) caused by mutations in superoxide dismutase-1 
(SOD1) are inclusions containing sOD1 in motor neurons. 
here, we searched for sOD1-positive inclusions in 29 
patients carrying aLs-linked mutations in six other genes.
Methods a panel of antibodies that specifically 
recognise misfolded sOD1 species were used for 
immunohistochemical investigations of autopsy tissue.
results The 18 patients with hexanucleotide-repeat-
expansions in C9orf72 had inclusions of misfolded wild 
type (WT) sOD1WT in spinal motor neurons. similar 
inclusions were occasionally observed in medulla 
oblongata and in the motor cortex and frontal lobe. 
patients with mutations in FUS, KIF5A, NEK1, ALSIN or 
VAPB, carried similar sOD1WT inclusions. Minute amounts 
of missOD1WT inclusions were detected in 2 of 20 
patients deceased from non-neurological causes and in 
4 of 10 patients with other neurodegenerative diseases. 
comparison was made with 17 patients with 9 different 
SOD1 mutations. Morphologically, the inclusions in 
patients with mutations in C9orf72HRE, FUS, KIF5A, 
NEK1, VAPB and ALSIN resembled inclusions in patients 
carrying the wildtype-like SOD1D90a mutation, whereas 
patients carrying unstable SOD1 mutations (a4V, V5M, 
D76Y, D83G, D101G, G114a, G127X, L144F) had larger 
skein-like sOD1-positive inclusions.
Conclusions and relevance abundant inclusions 
containing misfolded sOD1WT are found in spinal and 
cortical motor neurons in patients carrying mutations in 
six aLs-causing genes other than SOD1. This suggests 
that misfolding of sOD1WT can be part of a common 
downstream event that may be pathogenic. The new 
anti-sOD1 therapeutics in development may have 
applications for a broader range of patients.
INTrOduCTION
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative syndrome characterised by adult-onset 
progressive loss of motor neurons with a focal onset 
of progressive paresis and muscle wasting.1–3
Some 5%–10% of patients with ALS self-report 
a familial predisposition (fALS), and the remaining 
cases are denoted as sporadic ALS (sALS). Since 1993, 
mutations in 37 genes have been reported to predis-
pose to ALS. In Caucasians, the most commonly 
reported mutation is a GGGGCC repeat-expansion 
in C9orf72 (C9orf72HRE), found in 8%–10% of 
patients with ALS. Missense, substitution or dele-
tion mutations in the genes encoding superoxide 
dismutase-1 (SOD1), TAR-DNA-binding protein 43 
(TDP-43), fused in sarcoma (FUS) and kinesin heavy 
chain isoform 5A (KIF5A) are found in 2%–6% of 
European patients. The remaining gene mutations 
are rare. ALS is both genetically and clinically 
heterogeneous and the reported predisposing genes 
pleiotropic.4 Neuropsychological examinations 
and imaging studies can show involvement of the 
frontotemporal lobes,5 6 though this may remain 
subclinical.7 In particular, carriers of C9orf72HRE, 
FUS, VCP and TBK1 mutations may develop fronto-
temporal dementia (FTD) sometimes without overt 
ALS. Unfortunately, there have been few compar-
ative neuropathological examinations in patients 
with different gene defects.
The first ALS-causing gene discovered was SOD18 
and since 1993 more than 210 mutations have been 
found (http:// alsod. iop. kcl. ac. uk/).9 While some 
of the mutant SOD1s (eg, C6S, D90A, E100K, 
L117V) are sufficiently stable and active to yield 
normal SOD1 activity in human tissues,10 others, 
for example, A4V, V5M, D76Y, D83G, G127Gfs*5 
(alias ‘G127X’) are unstable, are rapidly targeted 
for degradation and can only be detected in minute 
amounts.11 12
Neuronal inclusions containing aggregated 
SOD1 are recognised pathological hallmarks of 
ALS caused by SOD1 mutations in patients and 
in transgenic (Tg) animal models overexpressing 
mutant human (h) SOD1s.11 13 In the Tg models, 
two structurally different strains have been found.14 
When inoculated into the lumbar spinal cord of 
adult mice, both strains induce cell-to-cell propa-
gating templated hSOD1 aggregation primarily in 
the motor neurons resulting in rapidly progressing 
ALS-like fatal diseases.15 Similar effects have been 
obtained inoculating SOD1-aggregates purified 
from the spinal cord of a patient with the SOD1G127X 
mutation.16 This prion-like action could be the 
primary pathogenic mechanism of SOD1-provoked 
ALS, which prompts exploration of SOD1 in ALS 
caused by other genes.
Previously, we examined spinal cord tissue 
from 37 patients with sALS and found numerous 
inclusions containing misfolded wild-type SOD1 
(misSOD1WT) in the cytoplasm and nuclei of neurons 
and glial cells.17 18 The presence of misSOD1WT 
in motor neurons of patients with ALS was later 
observed by other groups with the differences 
that antibodies against other SOD1-epitopes were 
used and inclusions were not found in all patients 
studied.19–22 Supporting that misSOD1WT may cause 
neurodegeneration, expression of hSOD1WT in Tg 
Bibliotek. Protected by copyright.
 o
n
 O
ctober 17, 2019 at Kobenhavns Universitets
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2018-319386 on 16 April 2019. Downloaded from 
862 Forsberg K, et al. J Neurol Neurosurg Psychiatry 2019;90:861–869. doi:10.1136/jnnp-2018-319386
Neurodegeneration
Table 1 Summary of clinical features of the 46 patients with ALS/FTD
Case Mutated gene diagnosis a.o. First symptom d.d. c.i. sex p.m.
1 C9orf72HRE ALS 64 Hand 25 No M 1.5
2 C9orf72HRE fFTD 60 Disinhibition 168 Yes M 1
3 C9orf72HRE fALS 59 Hand 36 No M 4
4 C9orf72HRE fALS-FTD 51 Disinhibition 43 Yes M 2.5
5 C9orf72HRE sPBP 69 Bulbar 21 No M 3
6 C9orf72HRE ALS 63 Leg 32 No M 1.5
7 C9orf72HRE fALS 58 Leg 18 No M 3
8 C9orf72HRE fALS 49 Arm 36 No M 1
9 C9orf72HRE fALS 51 Arm 130 No M 2
10 C9orf72HRE fALS 66 Arm 29 No M 2
11 C9orf72HRE PBP+FTD 76 Bulbar 60 Yes F 1.5
12 C9orf72HRE fALS 53 Leg 28 No F 0.5
13 C9orf72HRE sPBP 72 Bulbar 35 Yes F 1
14 C9orf72HRE fALS +FTD 67 Leg 35 Yes M 1.5
15 C9orf72HRE fALS 54 Arm 12 No F 2
16 C9orf72HRE+KIF5A fFTD 60 Disinhibition 133 Yes M 3
17 C9orf72HRE+KIF5A fALS 63 Leg 30 No F 2
18 C9orf72HRE+KIF5A ALS 44 Leg 65 n.a. M 0.5
19 KIF5A ALS 61 Arm 13 No F 1.5
20 KIF5A homozygous sALS 61 Leg 61 No F 1
21 KIF5A PBP 67 Bulbar 27 No F 1
22 KIF5A ALS 67 Thoracic 17 No M 1
23 KIF5A PMA 68 Arm 63 n.a. F 1.5
24 KIF5A PBP 65 Bulbar 13 No M 1.5
25 NEK1 R812X fALS 75 Hand 38 Slight F 1.1
26 VAPB S160delS sPBP 55 Bulbar 43 Yes M 0.5
27 FUS R495X fPBP 16 Bulbar 10 No F 4
28 FUS Q23L sPBP 35 Bulbar 175 Yes M 2.5
29 ALSIN+KIF5A sALS 50 Legs 224 Yes M 2
30 SOD1 V5M fALS 71 Leg 40 No M 2.2
31 SOD1 A4V+KIF5A fALS 73 Arm 10 Yes F 1.9
32 SOD1 G127X fALS 72 Thoracic 24 No M 1.1
33 SOD1 G127X fALS 53 Thoracic 6 No M 1.5
34 SOD1 G127X fALS 59 Arm 32 No F n.a.
35 SOD1 G114A fALS 38 Arm 36 No M 1.5
36 SOD1 G114A fALS 29 Leg 14 Yes F 4
37 SOD1 D76Y fALS 49 Leg 204 No M n.a.
38 SOD1 D83G fALS 49 Leg 37 No F 2
39 SOD1 D101G fPMA 48 Arm 6 n.a. M n.a.
40 SOD1 L144F fALS 71 Hand 65 No M 0.2
41 SOD1 D90A fALS 31 Leg 265 No M 2
42 SOD1 D90A fALS 58 Leg 101 No M 2
43 SOD1 D90A fALS 48 Leg 316 No M 1.5
44 SOD1 D90A fALS 53 Leg 131 No F 2.5
45 SOD1 D90A fALS 56 Leg 174 No M 1.5
46 SOD1 D90A fALS 38 Leg 60 No F 2
Cases nr 20, 29 and 41—46 were homozygous, all othersheterozygous for the respective genes.
ALS, amyotrophic lateral sclerosis; a.o, age at onset (years); c.i., cognitive impairment; d.d., disease 
duration (months); fFTD, familial frontotemporal dementia; F/M, female/male; p.m, postmortem time 
(days).
mice result in a fatal ALS-like disease with neuronal inclusions 
containing human misSOD1 aggregates.23 Also, in vitro studies 
in which motor neurons are cocultured with astrocytes derived 
from patients with ALS suggests an involvement of misSOD1WT 
in the pathogenesis.24 Collectively, there is emerging evidence 
that misSOD1WT is neurotoxic and participate in ALS pathogen-
esis in general and not only in patients carrying mutations in 
SOD1.
In the present study, we investigated whether inclusions 
containing misSOD1WT are present in patients carrying muta-
tions in six other ALS-causing genes.
MATerIAls ANd MeThOds
human subjects
Since 1993, tissue has been collected at autopsy at Umeå Univer-
sity Hospital, Sweden from patients with ALS and FTD. The 
EFNS Criteria for Managing ALS25 and the Neary Criteria for 
FTD26 were used to set the diagnosis. Blood leucocyte DNA 
from autopsied patients (n=97) was analysed for a panel of 
ALS-linked genes.12 27 28 Of these patients, 18 had C9orf72HRE 
(confirmed by Southern blot in CNS tissue),29 2 had FUS muta-
tions, 1 an ALSIN mutation (censored, manuscript in prepara-
tion), 1 a VAPB mutation, 1 a NEK1 mutation6 and 11 had SOD1 
mutations. Eleven patients carried the coding rs113247976 SNP 
(P986L) in KIF5A recently found to predispose to ALS, three of 
these being double mutants C9orf72HRE plus rs113247976 and 
one A4V SOD1 plus rs113247976 SNP.28
Six additional patients with SOD1 mutations were obtained 
from Danish and Swiss pathology units. Similar tissues were 
obtained from 10 control patients with other neurodegenerative 
conditions and from 20 patients without neurological diseases 
(table 1, online supplementary table 1).
All procedures were performed in accordance with the 
1964-Helsinki Declaration with amendments and were 
approved by the Ethical Review Boards for Medical Research 
at the relevant institutions in Sweden, Denmark and Switzer-
land. Informed consent for performing autopsies for research 
purposes was obtained from the patients and/or the next of kin.
Tissue preparation and staining for missOd1
Tissue samples from the spinal cord (cervical, thoracic and 
lumbar regions), medulla oblongata, motor cortex, frontal lobe 
and cerebellum were collected and fixed by immersion in 4% 
paraformaldehyde in 0.1 M Na phosphate buffer, pH 7.4. After 
fixation, tissues were embedded in paraffin, sectioned (4 µm), 
and stained with H&E. The antigen retrieval procedure is essen-
tial for detecting misSOD1 and should be mild, since heavily 
denaturing protocols may cause misfolding of the abundant 
natively folded SOD1. A well-functional retrieval treatment for 
sections is 10 min in preheated citrate buffer, pH 6.3, without 
boiling.18
Immunohistochemical staining (IHC) was initially performed 
using the ES system and ES reagents and, from 2014, by the more 
sensitive BenchMark XT automated staining system (both from 
Ventana Medical System, Illkirch, France) and aminoethylcarba-
zole or Fast Red was used for development. For immunofluo-
rescent studies, a corresponding fluorescent-labelled secondary 
antibody was used. Sudan Black diluted to 0.3% was used to 
avoid autofluorescence. The anti-SOD1 antibodies were diluted 
to a final concentration of 0.962 µg/mL for 131–153 Ra-ab, 3.7 
µg/mL for 57–72 Ra-ab and 1.612 µg/mL for G127X Ra-ab. 
The sections were examined using a BX53 light microscope 
(Olympus) and by confocal laser microscopy using a Zeiss LSM 
710 confocal microscope and were analysed using the Zen 2011 
SP7 software. The presence of intracellular misSOD1 inclusions 
was rated by two independent examiners according to a 4-point 
semiquantitative scale.18
resulTs
Antibodies specifically detect misfolded sOd1
SOD1 is abundant in the CNS constituting 0.1% of the tissue 
protein.11 17 Carriers of SOD1 mutations show inclusions 
containing misfolded aggregated SOD1. It is estimated that ≈1% 
of the total SOD1 protein is contained in such inclusions.11 30 
Bibliotek. Protected by copyright.
 o
n
 O
ctober 17, 2019 at Kobenhavns Universitets
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2018-319386 on 16 April 2019. Downloaded from 
863Forsberg K, et al. J Neurol Neurosurg Psychiatry 2019;90:861–869. doi:10.1136/jnnp-2018-319386
Neurodegeneration
Any misSOD1 inclusions occurring in patients with ALS who 
lack mutations in SOD1 are likely to be equally scarce. Thus, 
to detect such species, antibodies that lack reactivity with 
natively folded SOD1 must be used. Use of Rabbit 1, a Ra-ab 
raised against native SOD1 with native/denatured reactivity 
ratio of 0.7/1,31 is found to stain tissues heavily obscuring detec-
tion of inclusions containing misSOD1 (online supplementary 
figure 1C-D). Moreover, the handling of tissue specimen and 
antigen retrievals have to be lenient to prevent misfolding of 
native SOD1. We have developed a panel of antibodies, raised 
against peptides in the human SOD1WT sequence, which only 
react with disordered or misSOD1 species but show no reactivity 
against natively folded human SOD1. They were highly specific 
for SOD1 in western blots of human CNS tissue extracts.17 18 
The two primary antibodies used here were rabbit anti-human 
antibodies (Ra-ab) to misfolded SOD1, raised against peptides 
corresponding to amino acids (aa) 57–72 and aa131-153. The 
57–72 Ra-ab and 131–153 Ra-ab were chosen because they are 
well characterised17 18 and detect misfolded SOD1 in human 
tissue studies equally well. For detection of mutated SOD1 in 
patients with the SOD1 truncating mutation SOD1G127X, we 
developed a mutant-specific peptide antibody, G127X Ra-ab, 
directed against the neopeptide sequence unique to this muta-
tion (aa 123-127GQRWK-stop). This antibody reacts exclusively 
with the mutant protein.11 To test the specificity for misSOD1 in 
histopathological studies, the 131–153 Ra-ab was preincubated 
with the immunising peptide in increasing concentrations. This 
resulted in gradual and finally full disappearance of immunore-
activity (online supplementary figure 1E-H).
Inclusions containing misSOD1WT can be seen in patients carrying 
C9orf72HRE
Different regions of the brain and spinal cord from 18 patients 
carrying C9orf72HRE were stained for misSOD1 and analysed. 
We found small dot-like granular inclusions of misSOD1WT in 
spinal cord motor neurons in all 18 patients (tables 2 and 3), 
irrespective of whether the clinical diagnosis was ALS, FTD or 
both. The inclusions measured 0.5–3 µm were scattered in the 
cytoplasm of motor neurons and were particularly abundant in 
the soma (figure 1A,B,D and figure 2F–H) but also present in 
axons (figure 1A,B). The proportion of spinal motor neurons 
carrying misSOD1WT inclusions varied between patients; usually, 
only a few motor neurons per section carried misSOD1WT inclu-
sions. However, in some patients, the proportion was higher. 
Inclusions were found at all levels of the spinal cord (cervical, 
thoracic and lumbar) in most patients (table 3). MisSOD1WT 
inclusions were also present in the neurons of Clark’s nuclei. 
Furthermore, small inclusions of misSOD1WT were found in the 
hypoglossus (figure 3D), vagus, facialis and accessorius nuclei. 
The inferior olivary nucleus did not show misSOD1WT inclusions 
and was normal in most patients.
In the motor cortex, degenerated neurons containing 
numerous small misSOD1WT inclusions were detected in 7 of 
12 C9orf72HRE patients investigated, similar in size to the 
ones seen in spinal motor neurons (figure 3B,C and table 2) and 
located both in the cytoplasm and the nucleus. The proportion 
of motor cortex neurons that carried misSOD1WT inclusions 
was much smaller than the proportion of spinal motor neurons. 
In the frontal cortex, 11 out of 16 patients with C9orf72HRE 
carried misSOD1WT inclusions. Noticeably, in some patients, 
senile plaques were seen in the motor and frontal cortex, these 
stained heavily for misSOD1WT.
In the cerebellum of all 12 patients investigated, loss of Purkinje 
cells and degeneration of white matter was observed. Staining 
with anti-misSOD1 antibodies revealed misSOD1WT-stained glial 
cells surrounding either degenerated Purkinje cells or empty 
baskets. Staining was also found in the neuropil in both grey 
and white matter as well as in glial cells in the same regions 
(online supplementary figure 1A, B). In the granular and molec-
ular layers of the cerebellum, p62-positive neuronal cytoplasmic 
inclusions were observed, a finding proposed to be pathogno-
monic for this subgroup of ALS.32 No misSOD1WT staining was 
seen in the granular layer in the patients with C9orf72HRE.
Two of the patients with C9orf72HRE were siblings, one with 
FTD and the other with ALS (patients 2 and 3, respectively, 
table 2). The sibling with ALS had a significant loss of spinal 
motor neurons, whereas the sibling with FTD appeared to have 
a normal number of spinal motor neurons. However, both had 
misSOD1WT inclusions of similar morphology in motor neurons 
at all levels of the spinal cord. No misSOD1WT inclusions were 
detected in the medulla oblongata. Comparing their frontal 
cortices, the sibling with FTD had many extracellular senile 
plaques which stained heavily for misSOD1WT and amyloid-β. 
This was not seen to the same extent in the ALS sibling. In both, 
misSOD1WT was rarely observed in cortical glial cell nuclei 
(table 2).
Patients with FUS, NEK1, KIF5A, VAPB and ALSIN mutations
We found granular inclusions of misSOD1WT in motor neurons 
of the spinal cord in all patients with FUS, NEK1, KIF5A, VAPB 
or ALSIN mutations (figures 1C,E–G and 2I and table 2). The 
misSOD1WT-positive inclusions were morphologically similar 
to the ones observed in patients with C9orf72HRE and in 
patients with apparently sporadic ALS.17 Moreover, misSOD1WT 
pathology in the patients with FUS, NEK1, KIF5A, VAPB or 
ALSIN mutations included all levels of the spinal cord and 
brainstem motor nuclei (figure 3E,G), areas of the motor cortex 
(figure 3A), frontal lobe and the cerebellum. In the patients 
with FUS mutations, large cytoplasmic FUS-positive inclusions 
were found in the spinal cord and medulla oblongata when 
stained with an anti-FUS antibody. In the cerebellum, the same 
type of histopathology was observed as in the patients with 
C9orf72HRE, which included staining of misSOD1WT in glial 
cells of the molecular and granular layers surrounding degen-
erated Purkinje cells. The patients with VAPB and ALSIN muta-
tions in particular had these changes, whereas the cerebellum in 
the patients with FUS mutations was less affected. We conclude 
that all studied patients with FUS, NEK1, KIF5A, VAPB and 
ALSIN mutations had misSOD1WT inclusions in the spinal cord 
and brainstem motor nuclei and occasionally also in the motor 
cortex and frontal lobe.
Comparison with patients carrying different SOD1 mutations
For comparison, we stained tissue from 17 patients carrying 
SOD1 mutations (tables 2 and 3). The six patients homozy-
gous for the SOD1D90A mutation had small granular inclusions 
(figure 1l) morphologically similar to the inclusions described 
above in patients carrying mutations in C9orf72HRE, FUS, 
NEK1, KIF5A, ALSIN and VAPB and previously in sALS.17–19 22 
This could be expected since the SOD1D90A mutation produces 
an essentially fully stable SOD1D90A protein with biophys-
ical properties of SOD1WT.33 All patients with the SOD1D90A 
mutations had mild cortical atrophy with neuronal loss, reac-
tive gliosis and microvacuolisation of the three superficial 
cortical laminae. MisSOD1D90A inclusions in the motor cortex 
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Table 2 Immunohistochemical results of staining for misfolded SOD1 using the misSOD1 peptide antibodies: 131–153 Ra-ab (cases #1–31, #35–
56) and G127X Ra-ab (cases #32–34)
Case Mutated gene
spinal cord Medulla oblongata Motor cortex Frontal lobe Cerebellum
NCI GI NCI GI NCI GI NCI GI NCI GI
1 C9orf72HRE ++ ++ ++ ++ ++ +++ + +++ ++ ++
2 C9orf72HRE ++ ++ – + n.a. n.a. – + – +
3 C9orf72HRE ++ ++ – – n.a. n.a. – – – –
4 C9orf72HRE ++ +++ +++ +++ + +++ + ++ + ++
5 C9orf72HRE +++ +++ +++ +++ – +++ ++ +++ + +++
6 C9orf72HRE ++ +++ + +++ n.a. n.a. n.a. n.a. n.a. n.a.
7 C9orf72HRE ++ ++ ++ ++ – ++ + ++ + ++
8 C9orf72HRE ++ ++ ++ ++ n.a. n.a. + ++ n.a. n.a.
9 C9orf72HRE ++ ++ n.a. n.a. n.a. n.a. n.a. n.a. – +
10 C9orf72HRE ++ +++ n.a. n.a. + ++ ++ ++ n.a. n.a.
11 C9orf72HRE +++ ++ n.a. n.a. ++ ++ ++ ++ n.a. n.a.
12 C9orf72HRE ++ ++ n.a. n.a. – ++ + ++ n.a. n.a.
13 C9orf72HRE ++ ++ ++ ++ – ++ – ++ – ++
14 C9orf72HRE + + + ++ + ++ – ++ – ++
15 C9orf72HRE + ++ + ++ + ++ + ++ – ++
16 C9orf72+KIF5A +++ +++ +++ +++ ++ +++ ++ +++ + +++
17 C9orf72+KIF5A ++ ++ n.a. n.a. n.a. n.a. + + + +++
18 C9orf72+KIF5A ++ ++ n.a. n.a. – ++ ++ ++ n.a. n.a.
19 KIF5A + – + – – – – – – –
20 KIF5A homozyg ++ ++ n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
21 KIF5A + ++ n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
22 KIF5A + ++ n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
23 KIF5A + ++ – ++ – ++ – ++ – ++
24 KIF5A ++ ++ n.a. n.a. – + – + – ++
25 NEK1 R812X ++ +++ +++ +++ + +++ + +++ n.a. n.a.
26 VAPB S160delS + +++ ++ +++ ++ +++ ++ ++ + +++
27 FUS R495X ++ +++ + ++ – + – + – +
28 FUS Q23L ++ ++ + + n.a. n.a. – ++ – ++
29 ALSIN+KIF5A ++ +++ ++ +++ ++ ++ ++ ++ + +++
30 SOD1 V5M ++ + n.a. n.a. – + n.a. n.a. – –
31 SOD1 A4V+KIF5A ++ ++ ++ ++ – + – + – +
32 SOD1 G127X + +++ ++ + ++ + – + + +
33 SOD1 G127X + + + + n.a. n.a. – + – –
34 SOD1 G127X + + n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
35 SOD1 G114A + + n.a. n.a. n.a. n.a. – –
36 SOD1 G114A ++ ++ + + + + + ++ – +
37 SOD1 D76Y ++ – ++ – + + + – + –
38 SOD1 D83G + – n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
39 SOD1 D101G ++ – n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
40 SOD1 L144F + ++ n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
41 SOD1 D90A ++ +++ ++ ++ + +++ – + – +
42 SOD1 D90A ++ + – + – + – + – +
43 SOD1 D90A ++ ++ ++ ++ – + – + – –
44 SOD1 D90A ++ +++ + ++ – ++ – ++ + ++
45 SOD1 D90A ++ ++ ++ ++ + ++ n.a. n.a. – +
46 SOD1 D90A ++ ++ n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
47 N.D. Control – – – – – – – – – –
48 N.D. Control + – – – – – – – – –
49 N.D. Control + – – – – – – – – –
50 N.D. Control + ++ + ++ + + – + – ++
51 N.D. Control – – – – – – – – – –
52 N.D. Control + – – – n.a. n.a. n.a. n.a. n.a. n.a.
53 N.D. Control – – – – n.a. n.a. – – – –
54 N.D. Control – – – – n.a. n.a. n.a. n.a. n.a. n.a.
Continued
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Case Mutated gene
spinal cord Medulla oblongata Motor cortex Frontal lobe Cerebellum
NCI GI NCI GI NCI GI NCI GI NCI GI
55 N.D. Control – – – – n.a. n.a. n.a. n.a. n.a. n.a.
56 N.D. Control – – – – n.a. n.a. n.a. n.a. n.a. n.a.
Rating for misSOD1 inclusions: – no inclusion, + <25% of neurons had inclusions, ++ 25%–75% of neurons had inclusions, +++ >75% of neurons had inclusions.
GI, glial inclusion; n.a., not available; NCI, neuronal inclusions; N.D. Control, neurodegenerative control.
Table 2 Continued
Table 3 MisSOD1 immunohistochemical results
A 
Number of patients with missOd1 inclusions in spinal cord motor neurons 
sOd1 fAls
C9orf72hre 
expansion
Other Als 
mutations
Controls, 
neurodegenerative
Controls, non-
neurological
Cervical spinal cord 17 (17) 17 (18) 11 (11) 1 (10) 0 (14)
Thoracic spinal cord 16 (16) 15 (15) 11 (11) 1 (3) 0 (18)
Lumbar spinal cord 16 (16) 15 (16) 11 (11) 4 (10) 2 (19)
b 
Proportion of motor neurons with missOd1 staining
SOD1 fAls
C9orf72hre 
expansions
Other Als 
mutations
Controls, 
neurodegenerative
Controls, non-
neurological
Cervical spinal cord + (+ – ++) ++ (0 – +++) ++ (+ – ++) 0 (0 – ++) 0 (0)
Thoracic spinal cord + (+ – ++) ++ (+ – +++) ++ (+ – ++) 0, 0, ++* 0 (0)
Lumbar spinal cord + (+ – ++) ++ (0 – +++) ++ (+ – ++) 0 (0 – +) 0 (0 – +)
Table of findings from sections stained with the131–153 Ra-ab and 57–72 Ra-ab. Data for number of patients with misSOD1WT inclusions show the total number of patients 
in parenthesis. Data for proportion of misSOD1WT inclusions with staining are shown as median (range) referring to a four-tiered semiquantitative scale (0=no glial or motor 
neuron with staining; + ≤25% of the motor neurons with staining; ++=25%–75% of the motor neurons with staining; +++ ≥75% of the motor neurons with staining). The 
total number of patients in each group was as follows: 17 SOD1, 18 C9orf72HRE, 11 other ALS mutations (2 with FUS, 1 ALSIN+KIF5A, 1 VAPB, 1 NEK1, 6 KIF5A); 10 Controls 
neurodegenerative, 20 Controls non-neurological. Sections from all levels were not available from all patients. In total, of the 20 non-neurological controls, only two had some 
staining. *Since thoracic spinal cord only was available from three patients from the neurodegenerative control group each result is presented individually.
ALS, amyotrophic lateral sclerosis; fALS, familial ALS.
and frontal lobe were rarely observed in these patients. In 
contrast, staining for misSOD1 in patients with ALS hetero-
zygous for the mutations A4V, V5M, D76Y, D83G, D101G, 
G114A, L144F and G127X - all encoding unstable SOD1 
mutants11 12 34 revealed larger skein-like and Lewy body-like 
inclusions in addition to smaller granular misSOD1 inclusions 
(figures 1J,K–3H,I). Thus, there are (at least) two different 
morphologies of misSOD1 inclusions present in patients 
carrying pathogenic mutations in SOD1.
The SOD1G127X mutation results in a shift in the DNA 
coding frame and a neopeptide sequence of five amino acids 
127GQRWK-stop, truncating after codon 132, 21 amino acids 
short of end of the SOD1WT polypeptide.11 It is therefore suited 
for studying different misSOD1 inclusions. Staining with the 
anti-SOD1 antibody raised against the C-terminal end (131–153 
Ra-ab) revealed small and dot-like misSOD1 positive inclu-
sions in the motor neurons that resembled the staining seen in 
patients with sporadic and familial ALS lacking SOD1 mutations 
(figure 2A). This was observed in all three patients heterozygous 
for this mutation. Double staining with the 131–153 Ra-ab and 
the mutation-specific antibody G127X Ra-ab revealed separate 
inclusions of misSOD1 in motor neurons, without colocalisa-
tion (figure 2A–C): the large skein-like inclusions contain the 
misfolded SOD1G127X mutant protein, the small granular dot 
inclusions the misSOD1WT generated from the wild-type allele. 
Both types of inclusions in the same motor neuron were only 
observed in a few motor neurons per section. Most motor 
neurons had only one type of SOD1 inclusion and a few neurons 
lacked inclusions.
Control patients and reanalysis of spinal cord sections from patients 
with ALS and controls
To determine whether the misSOD1WT inclusions were specific 
for patients with ALS and FTD, brain and spinal cord tissue 
from 10 control patients with other neurodegenerative diseases 
were stained with the same anti-misSOD1 antibodies. Nine of 
10 controls did not show misSOD1WT inclusions anywhere in 
the spinal cord or brain (table 2, figures 1I and 3F). A single 
patient diagnosed with epilepsy after a cerebral infarction had 
some misSOD1WT inclusions in the spinal cord and hypoglossal 
nucleus. Neuronal cytoplasmic misSOD1WT inclusions were also 
seen to the same extent as in the motor cortex of patients with 
ALS, but the frontal cortex and cerebellum were blank. We addi-
tionally analysed spinal cord sections from cervical, thoracic and 
lumbar regions of 20 patients with non-neurological diseases 
(online supplementary table 1) with the anti-misSOD1 anti-
bodies. No inclusions of misSOD1WT were observed in any of 
these (figure 2E).
The above reported IHC investigations were carried out 
over a period of 14 years. During this time, the staining equip-
ment was changed in our lab. For control purposes, we recently 
restained and re-examined in parallel lumbar spinal cord spec-
imen from all 30 controls and 38 (of the 46) patients with ALS 
at the same time (CNS tissues were no longer available from two 
patients with C9orf72 and six patients with SOD1 mutations). 
Two different antibodies, 57–72 Ra-ab and 131–153 Ra-ab—tar-
geting the active site and the carboxy end of the SOD1 protein, 
respectively—were used to ascertain the specificity for misSOD1 
in the stainings. Identical protocol was used for all specimen. 
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Figure 1 Inclusions of missOD1WT in spinal cord sections of patients 
with mutations in six aLs/FTD-associating genes. MissOD1WT was present 
in histological sections from patients with aLs carrying C9orf72HRE (a–B, 
cases #2 and #8), NEK1 mutation (c, case #25), C9orf72HRE mutation (D, 
case #16), FUS mutation (e, case #27), KIF5A mutation (F, case #19), alsin 
mutation (G, case #29), VAPB mutation (h, case #26), SOD1D76Y mutation 
(J, case #37), SOD1a4V mutation (K, case #31) and SOD1D90A homozygous 
mutation (L, case #43), but not in a neurodegenerative control case (I, 
case #47). all sections were stained with the 131–153 Ra-ab peptide 
antibody. In panels (a–h), multiple small granular cytoplasmic inclusions 
of missOD1WT can be seen in motor neurons with a size of approximately 
0.5–3 µm. In panel L, staining of the wt-like SOD1D90A mutant is shown. 
Note the morphological similarity between panel L and panels a–h, where 
missOD1WT is stained. In panels J and K, the SOD1 mutations D76Y and 
a4V, which give rise to unstable sOD1 proteins, are found to show skein-
like cytoplasmic sOD1 inclusions in motor neurons. scale bars: a–F and I 50 
µm; G-h, J–L 30 µm. aLs, amyotrophic lateral sclerosis.
Figure 2 Inclusions of missOD1 observed in human spinal cord motor 
neurons. Micrographs showing lumbar ventral horn motor neurons 
from two patients with the SOD1G127X mutation (a–c, case #33 and D, 
case #32), a non-neurological control (e, case #64), three patients with 
C9orf72HRE mutation (F–h, cases #1, #11 and #5) and a FUS mutation (I, 
case #27). panels a–c show sections double-labelled with the 131–153 
Ra-ab peptide antibody which stains a segment of the sOD1 protein that 
is absent in the sOD1G127X mutant, and therefore only stains missOD1WT 
(a,c, green fluorescence) and the G127X Ra-ab which only recognises the 
mutated G127X sequence (B,c, red fluorescence). The merged picture of 
green and red channel scans show that this neuron carries inclusions of 
both mutated sOD1 (seen here in the axon as red) and of missOD1WT (seen 
here in the soma as green). The mutated and missOD1WT inclusions do 
not colocalise (c). panel D was stained with the G127X Ra-ab and panels 
e–I were stained with the 57–72 Ra-ab peptide antibody. Note the small 
dot-like granular cytoplasmic inclusions of missOD1 in motor neurons 
(F–I) which is not seen in the non-neurological control (e). The mutated, 
unstable sOD1G127X protein has more of a skein-like appearance (D). scale 
bars: a–G, 50 µm, h 30 µm, I 20 µm.
The identities of the restained sections were coded and were 
independently examined by two neuropathologists (KF, TB).
The results are summarised in figure 4, online supplementary 
figure 2 and supplementary table 2. The two examiners assessed 
the sections in principle equally, the only differences being a few 
one step differences in gradings of the SOD1 stainings in patients 
with ALS, online supplementary table 2. In these cases, both grad-
ings are shown. All the patients with ALS without SOD1 muta-
tions again showed the misSOD1WT-positive granular inclusions. 
They were easily detected and had the same shape and locations 
as seen in the previous older stainings. The misSOD1WT staining 
in the neurodegenerative control #50 was again seen (online 
supplementary figure 2 AI). However, the principal difference 
from the previous analyses was that misSOD1WT staining was 
now seen in three more neurodegenerative control (online 
supplementary figure 2 AG, AH, AK), which did not appear in 
the previous stainings (table 2). Two of these patients had Parkin-
son’s disease and one had Alzheimer’s disease. Noticeably, only 
a few motor neurons were positive. Moreover, also two of the 
non-neurological controls were when restained now graded as 
positive since a few motor neurons were positive (online supple-
mentary figure 2 AQ, AW).
The outcomes of examinations of sections stained with two 
different anti-SOD1 peptide antibodies (57–72 Ra-ab, 131–153 
Ra-ab) were almost identical (figure 4 and online supplementary 
table 2). This proves that the component that becomes stained 
in the granules is indeed misSOD1WT. The 131–153 Ra-Ab gives 
generally less background staining and was therefore chosen for 
most of the histochemical panels shown.
dIsCussION
We here report the finding of misSOD1WT-positive intracyto-
plasmic inclusions in motor neurons of patients lacking SOD1 
mutations but carrying pathogenic mutations in six other 
ALS-causing genes C9orf72HRE, FUS, NEK1, KIF5A, ALSIN 
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Figure 3 histological sections from the motor cortex and medulla 
oblongata of patients carrying different aLs-causing mutations. sections 
were stained with the 131–153 Ra-ab peptide antibody. panels a–c 
show Betz cells in the motor cortex of patients with a VAPB mutation, 
(a, case #26) and C9orf72HRE mutation (B, case #13 and c, case #16). 
small dot-like cytoplasmic inclusions of missOD1WT are apparent in the 
Betz cells (a–c). panels D–I show neurons in the medulla oblongata of 
patients with C9orf72hRe (D, case #15), NEK1 mutation (e, case #25), a 
neurodegenerative control (F, case #55), KIF5A mutation (G, case #19), 
the SOD1a4V mutation (h, case #31) and the SOD1D76Y mutation (I, case 
#37). In panels D, e and G, inclusions of granular missOD1 are observed in 
neurons of the hypoglossal nucleus. Note the mutated sOD1 protein, which 
appears skein-like in panels h–I compared with the granular missOD1WT 
protein (appearing as granular intracytoplasmic dots in panel D (e and 
G). scale bars: a 100 µm; B-G 50 µm, h-I 30 µm. aLs, amyotrophic lateral 
sclerosis.
Figure 4 Restaining of missOD1WT inclusions in lumbar spinal cord 
sections from patients carrying different aLs/FTD associated gene 
mutations as well as neurodegenerative and non-neurological controls. 
Micrographs show (a,B) C9orf72HRE (case #15), (B,c) FUS (case #27), 
(e,F) non-neurological control (case #71), (G,h) non-neurological control 
(case #72), (I,J) KIF5A (case #22), (K,L) alsin (case #29), (M,N) VAPB (case 
#26), (O,p) NEK1 (case #25), (Q,R) neurodegenerative control (case #54), 
(s,T) neurodegenerative control (case #55), U-V SOD1A4V (case #31), W-X 
SOD1D90A (case #43). For comparison, sections were stained with either 
the 131–153 Ra-ab (a, c, e, G, I, K, M, O, Q, s, U and W) or the 57–72 
Ra-ab (B, D, F, h, J, L, N, p, R, T, V and X). Multiple small dot-like inclusions 
are seen with both antibodies in all patients carrying different aLs/FTD 
associated gene mutations but are absent in the neurodegenerative and 
non-neurological controls. Note the high background staining when using 
57–72 Ra-ab. scale bars: a-X 100 µm for all micrographs.
and VAPB. The inclusions were small, numerous and scattered in 
the cytoplasm of motor neurons at all levels of the spinal cord, in 
the motor nuclei of the brain stem and occasionally in the motor 
and frontal cortex. They were seen in all 18 patients carrying 
C9orf72HRE, regardless of whether the patient had a ‘pure’ 
FTD diagnosis, pure ALS diagnosis or both. The morphology 
and shape of these inclusions resembled that of the inclusions 
described in sALS.17 Patients with other FTD-associated and 
ALS-associated mutations had similar inclusions that stained 
for misSOD1WT in the brain and spinal cord. The finding that 
misSOD1WT appears in small inclusions in all studied patients 
with ALS raises the question if these misSOD1WT inclusions are 
different from the ones formed from mutated SOD1.
In SOD1 Tg murine models overexpressing the G85R, G93A, 
D90A or G127X human SOD1 mutations, larger skein-like inclu-
sions are observed when stained with human misSOD1-specific 
antibodies. The misSOD1 in these SOD1 Tg murine models is 
aggregated. So far, two strains of aggregates (A and B) have been 
described which differ with regard to molecular structure.14 Both 
display prion-like properties and propagate further aggregation 
and phenotypically different ALS-like diseases when inoculated 
into the spinal cord of 100-day-old asymptomatic mice Tg for 
the human SOD1G85R mutation.15 In patients that carry unstable 
mutant SOD1s, morphologically similar misSOD1-IR inclusions 
are found.11 These also appear to contain aggregated SOD1, 
but the molecular structures have yet to be elucidated. Inocu-
lation of SOD1G127X aggregates purified from the spinal cord 
of patient no. 32 in this study (table 1) into the lumbar spinal 
cord of 100-day-old mice induced hSOD1-aggregate formation 
throughout the neuraxis concomitant with onset of ALS.16 Binary 
epitope mapping revealed that the human misSOD1 aggregates 
was of the A-type.16 Further inoculation studies of SOD1 aggre-
gates purified from other patients from this study are ongoing.
In patients homozygous for the stable wt-like mutant SOD1D90A, 
the motor neurons display small granular misSOD1D90A inclu-
sions. Whether these also have prion-like features as the larger 
inclusions found in the murine Tg models and in patients that 
carry unstable mutant SOD1s, remains to be determined. Still, 
this is the sole conspicuous misSOD1-IR structure found in post-
mortem tissue from the six SOD1D90A homozygous patients. The 
differences in morphology compared with patients with other 
SOD1 mutations might be related to their different molecular 
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stabilities. SOD1WT and stable SOD1 mutants might associate to 
form small granular inclusions whereas unstable mutant proteins 
could either be rapidly degraded or form fewer but larger inclu-
sions. Interesting implications follow from this observation: (1) 
inclusions of misSOD1 may be pathological hallmarks in all 
forms of ALS and (2) variation in morphology, distribution and 
number of aggregates may be used to distinguish different forms 
and stages of ALS.
Summarising the results of the initial staining and the 
restaining, 4 of 10 neurodegenerative controls had some inclu-
sions of misSOD1WT (online supplementary figure 2 AG-AI, AK, 
and supplementary table 2). One of the positive controls was 
a patient with epilepsy after cerebral infarction. Here, small 
granular cytoplasmic inclusions of misSOD1WT were seen in 
spinal cord motor neurons (online supplementary figure 2 AI), 
in the hypoglossus nuclei and in the motor cortex. No inclusions 
were found in the striatum, frontal cortex or mesencephalon. 
Speculatively, this control individual could have had clinically 
unrecognised early ALS and/or the cerebral infarction triggered 
a cascade of events resulting in misfolding of misSOD1WT that 
might not have prion-competent conformations15 but are still 
detected by our polyclonal antibodies. However, cerebrovascular 
injury has been proposed to be a risk factor for ALS.35 Two of the 
positive controls had Parkinson’s disease (online supplementary 
figure 2 AG, AK). Interestingly, inclusions of misSOD1WT have 
been found to accumulate in the brains of patients with Parkin-
son’s disease and suggests common mechanisms of misSOD1WT 
aggregation in both disorders.36 Moreover, neurodegenerative 
diseases with concomitant copathology is frequent.37
Two of the non-neurological controls also had a few motor 
neurons that stained positive for SOD1. One died of a dissec-
tion of the aorta and the other of myocardial infarction (online 
supplementary figure 2 AQ, AW). The first showed small areas 
of infarction in the spinal cord. As also noted earlier in senile 
plaques, the state of the tissue might thus affect the immunoreac-
tion found. All other 24 controls stained negative for misSOD1 
in all studied tissue specimens, demonstrating major differences 
between patients with ALS and controls.
The presence of misSOD1WT in postmortem CNS tissue 
of sALS and fALS without SOD1 mutations is controversial: 
some studies support the result of the present study,17–22 but in 
other studies misSOD1 could not be detected in sALS38–40 or 
there were no differences between sALS and control individ-
uals.41 42 Reasons for these opposite results were discussed in 
a recent article22 and includes methodological differences (ie, 
the use of TRIS/EDTA buffers instead of citrate-based buffers, 
different preanalytical tissue handling, variable incubation times, 
different antibody dilutions). Guidelines for staining misSOD1 
were proposed.22 These guidelines were adhered to in this work. 
It should be noted that Ref. 21 was a blinded study of sALS cases 
compared with controls (some of these were the same as in this 
study) and using some of the anti-misSOD1 antibodies as in the 
present study.
The present morphological study does not prove that 
misSOD1WT causes neurodegeneration in patients carrying 
mutations in C9orf72HRE, FUS, NEK1, KIF5A, ALSIN or 
VAPB. Nor can we explain how patients with a massive intronic 
GGGGCC repeat-expansion in C9orf72 or a R495X-trunca-
tion in the mRNA-housekeeping FUS enzyme have inclusions 
of misSOD1WT in their motor neurons and with a morphology 
and similar pattern of cellular distribution as in patients with 
the SOD1D90A mutation. We speculate that whatever the initial 
pathogenic events are in patients carrying C9orf72HRE or coding 
mutations in FUS, NEK1, KIF5A, VAPB or ALSIN, eventually they 
converge to common downstream event(s) involving unfolding 
and misfolding of SOD1WT. For this to happen, the stabilising 
intrasubunit C57-C146 disulfide bond must be reduced and the 
stabilising Zn2+ cofactor released. If the generated misfolded 
SOD1 species are pathogenic and form SOD1WT prions, based 
on injection of SOD1 aggregates,15 16 this event may only have 
to occur in a limited number of cells, perhaps only once for 
the SOD1-prion cascade to be initiated. The finding that over-
expression of human SOD1WT in mice elicits a fatal ALS-like 
disease supports that SOD1WT can cause neurodegeneration.23 
The observation that all three patients heterozygous for the 
SOD1G127X mutation had inclusions with the truncated mutant 
SOD1G127X protein (easily recognisable because of its neopeptide 
sequence) and separate inclusions containing only misSOD1WT 
(detectable by the amino acid sequence that is missing in the 
mutated SOD1 protein) is interesting. It raises the possibilities 
that either the misfolding of SOD1WT is a secondary non-patho-
genic event in a stressed cell or that misfolded SOD1WT partici-
pates and could be pathogenic per se, raising the possibility that 
there could be more than one kind of SOD1 prions active simul-
taneously in patients with SOD1 mutations. Simply targeting 
a mutant SOD1 gene with tailored genetic inhibition therapy 
may therefore not be sufficient to halt disease progression. This 
observation is important, since new therapies targeting SOD1 are 
ongoing or are being planned. If SOD1 plays a role in subtypes of 
ALS without SOD1 mutations as our results suggest, then many 
patients may benefit from these new anti-SOD1 therapeutics.
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